Summit Therapeutics PLC (SMMT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Summit Therapeutics PLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 13.00 $ — 2% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -221.5%
- ROCE > 15% -217.4%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0% failed
- More than 10% revenue growth is expected for the coming year 1,617.3% passed
- Share count grows by less than 3% a year 57.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.3% failed
- Net debt below twice EBITDA 514 m net cash passed
- Operating cash flow covers the profits of the last three years 1,325 m failed
- Return on capital at 15% or higher, or up versus two years ago -217.4% failed
- Insiders hold at least 10% or are net buyers 83.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 118.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.86 | -1.25 – -0.59 | 3 | 19.4% | 12 |
| 12/31/2027 | -0.89 | -1.27 – -0.64 | 44 | -3.4% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.22 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.07 | – | 0 | – | – | -39 | -39 |
| 2025: Q1 | -0.07 | – | 0 | – | – | -47 | -48 |
| 2025: Q2 | -0.31 | – | 0 | – | – | -69 | -69 |
| 2025: Q3 | -0.31 | – | 0 | – | – | -93 | -93 |
| 2025: Q4 | -0.29 | – | 0 | – | – | -76 | -76 |
| 2026: Q1 | -0.24 | – | 0 | – | – | -93 | -93 |
| 2026: Q2 | -0.28 | 9.70 | – | – | – | -141 | -142 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -25 | -21 | -0.35 | 15 | -4 | 47 |
| 2017 | 14 | -26 | -20 | -0.31 | -21 | 14 | 76 |
| 2018 | 57 | 5 | 11 | 0.13 | -35 | 56 | 80 |
| 2019 | 43 | 15 | 5 | 0.15 | -27 | 61 | 75 |
| 2020 | 1 | -72 | -39 | -0.55 | -35 | 58 | 75 |
| 2021 | 2 | -86 | -86 | -0.93 | -54 | 62 | 84 |
| 2022 | 1 | -60 | -65 | -0.34 | -34 | 103 | 541 |
| 2023 | 0 | -478 | -482 | -0.78 | -61 | 61 | 161 |
| 2024 | 0 | -181 | -177 | -0.25 | -114 | 311 | 348 |
| 2025 | 0 | -1,094 | -1,080 | -1.44 | -240 | 489 | 558 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Summit Therapeutics Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf Entdeckung, Entwicklung und Vermarktung von patienten-, arzt-, betreuer- und gesellschaftsfreundlichen medizinischen Therapien.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 265 |
| Headquarters | Miami, FL |
| Address | 601 Brickell Key Drive, 33131 Miami, United States |
| Phone | 305 203 2034 |
| Website | smmttx.com |
| IPO Date | 5. Mar 2015 |
| ISIN | US86627T1088 |
| Stock Split | 1:1 on 09/21/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert W. Duggan | Co-CEO & Executive Chairman | 1945 |
| Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director | 1970 |
| Manmeet Singh Soni CPA | COO, CFO & Director | 1978 |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance | 1978 |
| Nathan LiaBraaten | Senior Director of Investor Relations | – |
| Elaine Carla Stracker J.D., Ph.D. | Chief Legal Officer | 1961 |
| Dave Gancarz CPA | Chief Business & Strategy Officer | – |
| Wang Clow Fong ScD | Chief Biometrics Officer | 1958 |
| Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer | 1971 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.